Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.

Subha V. Raman,Kan N. Hor,Wojciech Mazur,Andrea Cardona,Xin He,Nancy Halnon,Larry Markham,Jonathan H. Soslow,Michael D. Puchalski,Scott R. Auerbach,Uyen Truong,Suzanne Smart,Beth McCarthy,Ibrahim M. Saeed,Jeffrey M. Statland,John T. Kissel,Linda H. Cripe

DOI: https://doi.org/10.1161/JAHA.119.013501

IF: 6.106

2019-11-25

Journal of the American Heart Association

Abstract:Background Duchenne muscular dystrophy incurs nearly universal dilated cardiomyopathy by the third decade of life, preceded by myocardial damage and impaired left ventricular strain by cardiac magnetic resonance. It has been shown that (1) mineralocorticoid receptor antagonist therapy with spironolactone attenuated damage while maintaining function when given early in a mouse model and (2) low‐dose eplerenone stabilized left ventricular strain in boys with Duchenne muscular dystrophy and evident myocardial damage but preserved ejection fraction. We hypothesized that moderate‐dose spironolactone versus eplerenone would provide similar cardioprotection in this first head‐to‐head randomized trial of available mineralocorticoid receptor antagonists, the AIDMD (Aldosterone Inhibition in Duchenne Muscular Dystrophy) trial. Methods and Results This was a multicenter, double‐blind, randomized, noninferiority trial. Subjects were randomized to eplerenone, 50 mg, or spironolactone, 50 mg, orally once daily for 12 months. The primary outcome was change in left ventricular systolic strain at 12 months. Among 52 enrolled male subjects, aged 14 (interquartile range, 12–18) years, spironolactone was noninferior to eplerenone (∆strain, 0.4 [interquartile range, −0.4 to 0.6] versus 0.2 [interquartile range, −0.2 to 0.7]; P =0.542). Renal and pulmonary function remained stable in both groups, and no subjects experienced serious hyperkalemia. Infrequent adverse events included gynecomastia in one subject in the spironolactone arm and facial rash in one subject in the eplerenone arm. Conclusions In boys with Duchenne muscular dystrophy and preserved left ventricular ejection fraction, spironolactone added to background therapy is noninferior to eplerenone in preserving contractile function. These findings support early mineralocorticoid receptor antagonist therapy as effective and safe in a genetic disease with high cardiomyopathy risk. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT02354352. Clinical Perspective What Is New? In this first head‐to‐head study of available mineralocorticoid receptor antagonist drugs, spironolactone was noninferior to eplerenone in preserving cardiac contractility in boys with Duchenne muscular dystrophy. What Are the Clinical Implications? In patients at high genetic risk of dilated cardiomyopathy, initiation of a mineralocorticoid receptor antagonist while ejection fraction is preserved may stabilize cardiac function and attenuate progressive myocardial damage. Introduction Duchenne muscular dystrophy (DMD), the most common severe form of muscular dystrophy, is an X‐linked disorder in which the sarcolemmal protein dystrophin is effectively absent. Male patients with DMD typically die in the third and fourth decades of life of cardiopulmonary disease. 1 Mouse models of DMD, autopsy data, and in vivo human studies using cardiac magnetic resonance (CMR)–based late gadolinium enhancement (LGE) imaging have all shown that progressive myocardial damage occurs well before left ventricular ejection fraction (LVEF) becomes abnormal. 2 Decline in cardiac function portends complications, such as heart failure, arrhythmias, and sudden death. Patients with DMD do not manifest clinical signs of cardiomyopathy until LV dysfunction and myocardial fibrosis are advanced. Thus, sensitive biomarkers are required to afford timely therapy that preserves function and prevents complications. Echocardiography is widely used to assess LV function in patients with DMD; reproducibility is impacted by acoustic window that may be limited, particularly as body habitus changes over time, reducing its appeal for rare disease clinical trials of modest sample size. 3 CMR with LGE offers high reproducibility and identifies myocardial injury before decline in EF is apparent. 4 , 5 LV strain by CMR is a sensitive and early marker of LV systolic dysfunction in DMD and is measurably abnormal before EF declines. 6 < -Abstract Truncated-

cardiac & cardiovascular systems